Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis.
Yoshida
T
T
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Kameda
H
H
Masashi
A
A
Homma
M
M
Ikeda
Y
Y
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000328:Adult; D018592:Cross-Over Studies; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000652:urine; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D004791:Enzyme Inhibitors; D007093:Imidazoles; D013764:Tetrahydronaphthalenes; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C056295:nafagrel; D013930:Thromboxane-A Synthase; D007213:Indomethacin